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Treatment-by-Histology Interaction Analyses in Three Phase
III Trials Show Superiority of Pemetrexed in Nonsquamous
Non-small Cell Lung Cancer
Giorgio Scagliotti, MD,* Thomas Brodowicz, MD,†‡ Frances A. Shepherd, MD,§
Christoph Zielinski, MD,†‡ Johan Vansteenkiste, MD, Christian Manegold, MD,¶
Lorinda Simms, MSc, PStat,# Frank Fossella, MD,** Katherine Sugarman, MD,††
and Chandra P. Belani, MD‡‡
Introduction: Recently, histology has emerged as a predictive
factor for pemetrexed efficacy in non-small cell lung cancer
(NSCLC). These analyses evaluate whether the differential efficacy
of pemetrexed by NSCLC histology is reproducible and consistent
across three registration studies of different lines of therapy (first-
line/second-line and maintenance settings).
Methods: The reported studies for patients with advanced NSCLC
were pemetrexed versus docetaxel in previously treated patients
(N  571), cisplatin plus pemetrexed versus cisplatin plus gemcit-
abine in chemotherapy-naive patients (N  1725), and maintenance
pemetrexed plus best supportive care versus placebo plus best
supportive care (N  663). Cox models of overall survival (OS) and
progression-free survival (PFS) were used to test for a significant
treatment-by-histology interaction (THI). A significant THI indi-
cates that the efficacy benefit for pemetrexed relative to the control
arm is greater in patients with nonsquamous histology than in those
with squamous histology. Subsequent Cox models were used to
estimate hazard ratios for OS and PFS according to histology.
Results: Histology was well balanced between treatment arms in
each study. Across all three studies, no clinically relevant differ-
ences were observed for the safety profile of pemetrexed among
histologic groups. THIs were statistically significant in all three
studies for OS (p  0.001, 0.002, and 0.033, respectively) and PFS
(p  0.004, 0.002, and 0.036, respectively).
Conclusions: These analyses demonstrate a statistically significant
interaction between treatment effect and NSCLC histology, indicat-
ing superior efficacy of pemetrexed in nonsquamous patients com-
pared with other standard treatment options. Thus, histology is
consistently predictive of the improved efficacy of pemetrexed in
patients with nonsquamous NSCLC.
Key Words: Non-small cell lung cancer, Pemetrexed, Histology,
Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma,
Nonsquamous, Thymidylate synthase.
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Prognostic factors that have been associated with survivalin non-small cell lung cancer (NSCLC) include disease
stage at the time of diagnosis, performance status (PS), and
recent weight loss (10% of body weight). Although sex,
tumor size, and histology have also been shown to influence
outcomes, their impact has been marginal and without statis-
tical significance.1–4 Even when combination chemotherapies
including third-generation agents were considered, histology
was not definitively prognostic.5,6
Recently, histology has emerged as a predictive factor
for pemetrexed efficacy7–10 and a determinant of toxicity with
bevacizumab for patients with advanced NSCLC.11 Histori-
cally, the association of histology with clinical outcomes has
been inconsistent.9 A histologic diagnosis of adenocarcinoma
and female sex, Asian ethnicity, and never-smoking status
predicted higher response rates (RRs) for epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), but
only a nonsmoking history was predictive of a differentially
greater survival benefit.12–14 In advanced NSCLC, the predic-
tive role of nonsquamous histology for the efficacy of pem-
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etrexed therapy has been reported in the retrospective analy-
ses of two phase II studies15,16 and one phase III study,17 and
prospectively in two additional phase III studies.7,18,19
We further evaluated the differential efficacy of pem-
etrexed by histology in the second-line, first-line, and main-
tenance settings in the context of these three large phase III
studies.7,17–19 These randomized studies were selected be-
cause all met regulatory criteria for approval of pemetrexed in
different settings of disease treatment and were sufficiently
robust to allow treatment-by-histology interaction (THI) anal-
yses. The objective of these analyses was to evaluate the
differential efficacy of pemetrexed by NSCLC histology and
its reproducibility and consistency across the three studies in
three different settings of pemetrexed therapy.
PATIENTS AND METHODS
Patients
Details regarding the three studies have been published
previously.7,17,19 The second-line study had 571 previously
treated patients with advanced or metastatic NSCLC, the
first-line study had 1725 chemotherapy-naive patients with
NSCLC, and the maintenance study had 663 patients with
NSCLC who had not progressed after four cycles of plati-
num-based chemotherapy.7,17,19
All patients signed written informed consent before
treatment. The protocols were conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice guide-
lines and were approved by each participating institutional
ethics review board.
Study Designs and Treatments
The second- and first-line studies assessed overall sur-
vival (OS) as the primary end point using a noninferiority
design, whereas the maintenance trial was designed to dem-
onstrate superiority for the primary end point of progression-
free survival (PFS). Secondary objectives (which varied de-
pending on the study) included comparisons of PFS, OS,
tumor RR, duration of response, and toxicity.
Patients in the second-line study randomly received
either pemetrexed 500 mg/m2 as a 10-minute intravenous
(IV) infusion or docetaxel (Taxotere, Sanofi-Aventis, France)
75 mg/m2 as a 1-hour IV infusion on day 1, every 21 days.
Treatment continued until disease progression, unacceptable
toxicity, or a request for therapy discontinuation.
Patients in the first-line study randomly received either
cisplatin 75 mg/m2 plus pemetrexed (ALIMTA, Eli Lilly and
Company, USA) 500 mg/m2 on day 1 or cisplatin 75 mg/m2
on day 1 plus gemcitabine (Gemzar, Eli Lilly and Company,
USA) 1250 mg/m2 on days 1 and 8. Chemotherapy was
repeated every 3 weeks for a maximum of six cycles.
Patients in the maintenance study randomly received, in
a 2:1 ratio, pemetrexed 500 mg/m2 as a 10-minute IV infusion
on day 1 plus best supportive care or placebo (0.9% sodium
chloride) intravenously on day 1 plus best supportive care in
21-day cycles until disease progression. Patients and physi-
cians were blinded to treatment.
During study treatment, all patients received supple-
mentation with folic acid and vitamin B12 (except in the
second-line docetaxel arm) and all patients received prophy-
lactic dexamethasone (administered according to the pem-
etrexed or docetaxel prescribing information).
Comprehensive baseline and follow-up assessments,
including clinical laboratory tests and imaging studies, have
been reported previously. Toxicity evaluations were based on
Common Toxicity Criteria version 2.07,17 or Common Ter-
minology Criteria for Adverse Events version 3.0.19 Tumor
measurements were assessed every two cycles in the second-
line study using Southwest Oncology Group criteria17,20 and
in the first-line and maintenance studies using Response
Evaluation Criteria in Solid Tumors version 1.0.7,19,21
NSCLC histology was reported by each investigator
and grouped for statistical analyses into four types: adeno-
carcinoma, large cell carcinoma, squamous cell carcinoma,
and other NSCLC/unclassified.
Statistical Analyses
All patients who received at least one dose of study drug
were considered evaluable for safety analyses. All randomized
patients, on an intent-to-treat basis, were included in efficacy
analyses unless otherwise noted. For the purpose of these spe-
cific statistical analyses, results were dichotomized into two
histologic groups: patients with squamous cell histology and
patients with nonsquamous histology, which comprises adeno-
carcinoma, large cell carcinoma, and other NSCLC/unclassified.
Histology analyses were evaluated retrospectively in the second-
line study and prospectively (for prespecified subset analyses) in
the first-line and maintenance studies.
For all three studies, for the two histologic groups, the
Kaplan-Meier method22 was used to estimate unadjusted
within-arm medians (with 95% confidence intervals [CIs]),
and Cox proportional hazard models were used to estimate
covariate-adjusted between-arm hazard ratios (HRs) with
95% CIs. A THI analysis was also performed for all three
studies, which is a test for interaction based on multivariate Cox
models. A significant THI indicates a differential treatment
effect according to histology. The histologic group analysis
clarifies how the treatment effect differs by histology.
To test for covariate-adjusted THIs for both OS and PFS,
the Cox models included a treatment term (pemetrexed arm
versus control arm), a histology term (nonsquamous versus
squamous), and an interaction term (nonsquamous pemetrexed
arm versus all other), and terms for predefined baseline prog-
nostic factors. The baseline prognostic factors included PS,
disease stage, sex, and time since prior therapy for the second-
line study; PS, disease stage, sex, and basis of diagnosis for the
first-line study; and PS, induction response, East Asian ethnicity,
sex, age, and nonsmoker status for the maintenance study. The
interaction (THI) HR is the ratio of two HRs: the treatment effect
(OS or PFS) for nonsquamous patients divided by the treatment
effect (OS or PFS) for squamous patients:
HR (pemetrexed arm relative to control arm) for
nonsquamous patients  HR (pemetrexed arm relative to
control arm) for squamous patients.
An interaction HR less than 1.0 indicates that the benefit
for pemetrexed relative to the control arm is greater in patients with
nonsquamous histology than in those with squamous histology.
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RESULTS
Baseline Demographics
Patient and disease baseline characteristics were bal-
anced between arms for the three studies, as shown in Table 1.
Patient and disease characteristics within histologic groups
were also balanced and have been published previously for
the three studies.18,19
Efficacy
Second-Line Study of Pemetrexed Versus
Docetaxel
In the second-line study, THIs for OS and PFS were
statistically significant (OS, p  0.001 and PFS, p  0.004;
Table 2). Nonsquamous patients treated with pemetrexed had
significantly longer OS (HR  0.78; 95% CI: 0.61–1.00; p 
0.048; Figure 1) than those treated with docetaxel (Table 3).
Squamous patients had shorter OS (HR  1.56; 95% CI:
1.08–2.26; p  0.018) and PFS (HR  1.40; 95% CI:
1.01–1.96; p  0.046) on pemetrexed compared with do-
cetaxel. The efficacy of pemetrexed varied and favored
nonsquamous histology, whereas the efficacy of docetaxel
did not vary by histologic group.
In nonsquamous patients, numerically higher RRs oc-
curred in those treated with pemetrexed (11.5%) compared
with docetaxel (9.0%). In squamous cell carcinoma, patients
treated with docetaxel had numerically higher RRs than those
treated with pemetrexed (8.1% versus 2.8%; Table 3).
First-Line Study of Cisplatin Plus Pemetrexed
Versus Cisplatin Plus Gemcitabine
In the first-line study, THIs for OS and PFS were also
statistically significant (both p  0.002), demonstrating a
TABLE 1. Baseline Patient and Disease Characteristics for Randomized Patients for Three Pemetrexed Studies
Characteristics
Second-Line
Pemetrexed
vs. Docetaxel
First-Line Cisplatin  Pemetrexed
vs. Cisplatin  Gemcitabine
Maintenance
Pemetrexed
vs. Placebo
Pemetrexed
(n  283)
Docetaxel
(n  288)
Cisplatin  Pemetrexed
(n  862)
Cisplatin  Gemcitabine
(n  863)
Pemetrexed
(n  441)
Placebo
(n  222)
Median age (yr) 59 57 61 61 61 60
Female/Male (%) 31/69 25/75 30/70 30/70 27/73 27/73
Disease stage IIIB/IV (%) 25/75 25/75 24/76 24/76 18/82 21/79
ECOG PS 0/1/2 (%)a 20/69/11 18/70/12 35/65/— 36/64/— 40/60/— 38/62/—
Smoker (%) NAb NAb 73 74 74 71
Nonsquamous histology (%) 72 67 72 73 74 70
Squamous histology (%) 28 33 28 27 26 30
a Baseline ECOG PS data not available for some patients in each category.
b No smoking status data were collected.
n, number of patients; ECOG PS, Eastern Cooperative Oncology Group performance status; NA, not available.
TABLE 2. Treatment-by-Histology Interactions for Overall Survival and Progression-Free Survival for Three Pemetrexed Studies
Efficacy Parameters
Second-Line Pemetrexed
vs. Docetaxel (N  571)
First-Line Cisplatin  Pemetrexed
vs. Cisplatin  Gemcitabine
(N  1725)
Maintenance Pemetrexed
vs. Placebo (N  663)
Nonsquamousa
(n  399)
Squamous
(n  172)
Nonsquamousa
(n  1252)
Squamous
(n  473)
Nonsquamousa
(n  481)
Squamous
(n  182)
Overall survival
Adjusted HRb (95% CI) 0.78 (0.61–1.00) 1.56 (1.08–2.26) 0.84 (0.74–0.96) 1.23 (1.00–1.51) 0.70 (0.56–0.88) 1.07 (0.77–1.50)
Superiority p 0.048 0.018 0.011 0.050 0.002 0.678
Treatment-by-histology
interaction test pc
0.001 0.002 0.033
Progression-free survival
Adjusted HRb (95% CI) 0.82 (0.66–1.02) 1.40 (1.01–1.96) 0.95 (0.84–1.06) 1.36 (1.12–1.65) 0.47d (0.37–0.60)d 1.03d (0.71–1.49)d
Superiority p 0.076 0.046 0.349 0.002 0.0001d 0.896d
Treatment-by-histology
interaction test pc
0.004 0.002 0.036
a Nonsquamous histology comprises adenocarcinoma, large cell, and other histologies.
b HR 1.0 favors pemetrexed study arm; HR 1.0 favors comparator.
c Tests for statistically significant treatment-by-histology interactions were performed for progression-free survival and overall survival using covariate-adjusted Cox proportional
hazards models.
d Independently reviewed data.
CI, confidence interval; HR, hazard ratio; N, number of randomized patients; n, number of patients per histologic type.
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differential treatment effect for pemetrexed by histology,
with improved efficacy in patients with nonsquamous histol-
ogy (Table 2). Nonsquamous patients treated with cisplatin
plus pemetrexed had significantly longer OS (HR  0.84;
95% CI: 0.74–0.96; p  0.011; Figure 1) than those treated
with cisplatin plus gemcitabine (Table 3). Squamous
patients had shorter OS (HR  1.23; 95% CI: 1.00–1.51;
p  0.050) and PFS (HR  1.36; 95% CI: 1.12–1.65; p 
0.002) on cisplatin plus pemetrexed compared with cispla-
tin plus gemcitabine.
RRs for this study varied by histologic type. Numeri-
cally higher RRs occurred in the nonsquamous patients
treated with cisplatin plus pemetrexed (28.6%) compared
with nonsquamous patients treated with cisplatin plus gem-
citabine (22.2%). In patients with squamous cell carcinoma,
numerically higher RRs occurred in patients treated with
cisplatin plus gemcitabine (31.4% versus 23.4%; Table 3).
Maintenance Study of Pemetrexed Versus Placebo
In the maintenance study, THIs for OS and PFS were
also statistically significant (OS, p  0.033 and PFS, p 
0.036), demonstrating a treatment advantage for nonsqua-
mous patients receiving maintenance pemetrexed (Table 2).
Nonsquamous patients treated with pemetrexed had signifi-
cantly longer OS (HR  0.70; 95% CI: 0.56–0.88; p 
0.002; Figure 1) and PFS (HR  0.47; 95% CI: 0.37–0.60;
p  0.0001) than those treated with placebo (Table 3).
Squamous patients did not benefit from pemetrexed com-
pared with placebo, showing no significant difference for OS
(HR  1.07; 95% CI: 0.77–1.50; p  0.678) or PFS (HR 
1.03; 95% CI: 0.71–1.49; p  0.896). PFS results were based
on an analysis of independently reviewed data.
Independently reviewed RR data for this study also
varied by histologic group. Significantly higher (p  0.035)
RRs occurred in the nonsquamous patients treated with pem-
etrexed (3.4%) compared with placebo (0.0%). In patients
with squamous cell carcinoma, RRs were not significantly
higher (3.1% versus 1.8%; p  0.999; Table 3).
Probability
Although the three NSCLC studies targeted different
therapeutic settings (first line, maintenance, and second line),
they demonstrated a consistent treatment effect for pem-
etrexed regimens by histology for both OS and PFS. As such,
the multiplicative rule of mathematics can be applied to
determine and measure the probability of a given event (the
pemetrexed treatment effect) occurring in these three inde-
pendent settings. By multiplying each OS THI p value, the
chance of the histology effect being due to chance alone can
be evaluated as follows: 0.001  0.002  0.033 
0.000000066 or 1 in 15 million.
Postdiscontinuation Therapy
For all three studies, decisions regarding poststudy
therapy were at the discretion of the individual investigators.
Details regarding the types of agents administered have been
published previously; docetaxel was the most commonly used
chemotherapeutic agent.7,17,19 The use of postdiscontinuation
therapy did not differ significantly between pemetrexed arms
and comparator arms, with the exception of crossing over to
postdiscontinuation pemetrexed; however, the cross-over
rates were low (13–18%).7,19 The use of EGFR TKIs (erlo-
tinib or gefitinib) also did not differ significantly between
arms.7,17,19 The selection of postdiscontinuation therapies in
the histologic groups was similar to that of the overall study
groups.18,19
Safety
In all three studies, pemetrexed was well tolerated and
demonstrated a consistent safety profile (Table 4).7,17,19 Tox-
icities were also analyzed by histologic group, and results
have shown that the incidence of pemetrexed-related grade
FIGURE 1. The Kaplan-Meier overall survival curves for the
nonsquamous patient groups in each of the three studies
(the cisplatin plus pemetrexed versus cisplatin plus gemcit-
abine first-line study, the pemetrexed versus placebo mainte-
nance study, and the pemetrexed versus docetaxel second-
line study). CP, cisplatin-pemetrexed; CG, cisplatin-
gemcitabine; P, pemetrexed; PL, placebo; D, docetaxel.
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3/4 toxicities did not vary significantly by histologic
group,18,19 and the safety profile reported for pemetrexed
across the histologic groups was consistent with the results
reported for the overall study populations.18,19
DISCUSSION
The THI analyses of three large phase III studies7,18,19
confirm a treatment advantage for pemetrexed in patients
with nonsquamous NSCLC. In all these studies, baseline
patient and treatment characteristics were balanced between
arms, including histology, although histology was not a
randomization factor. Even when the pemetrexed treatment
effect on OS in the nonsquamous population was analyzed by
baseline characteristics, there was a consistent treatment
effect observed for pemetrexed across the subgroups.
The fact that studies allowed postdiscontinuation therapy
at the discretion of the investigator has lead to a potential bias to
associate the differential treatment effect of pemetrexed with the
poststudy therapy received, especially EGFR therapy (gefitinib
or erlotinib). Nevertheless, for the three studies, except for
pemetrexed, the selection of poststudy agents did not differ
significantly between study arms. Moreover, the selection of
therapies in the histologic groups reflected that of the overall
study populations,18,19 and there were no significant differences
between arms in the use of gefitinib or erlotinib.7,17,19 The
percentage of patients receiving postdiscontinuation therapy was
consistent with that of other published studies,23–25 and, in the
three studies examined, the OS data do not seem to be influenced
by the selection of poststudy therapy.7,18,19
Other chemotherapeutic agents have not demonstrated
a similar treatment effect by tumor histology.5,26 In addition,
large placebo-controlled studies of EGFR TKIs (gefitinib and
erlotinib) have not shown a significant interaction between
survival benefit and tumor histology.14,27
The differential activity of pemetrexed by histology was
not observed in a phase III NSCLC study from Norway.28 In this
TABLE 3. Summary of Overall Survival, Progression-Free Survival, and Response Rate by Histologic Group for Three
Pemetrexed Studies
Histologic Group
Second-Line Pemetrexed
vs. Docetaxel
(N  571)
First-Line Cisplatin  Pemetrexed
vs. Cisplatin  Gemcitabine
(N  1725)
Maintenance Pemetrexed
vs. Placebo
(N  663)
Pemetrexed Docetaxel Cisplatin  Pemetrexed Cisplatin  Gemcitabine Pemetrexed Placebo
Squamous cell carcinoma (n) 78 94 244 229 116 66
Median OS (mo) 6.2 7.4 9.4 10.8 9.9 10.8
HR (95% CI) p 1.56 (1.08–2.26) 0.018 1.23 (1.00–1.51) 0.050 1.07 (0.77–1.50) 0.678
Median PFS (mo) 2.3 2.7 4.4 5.5 2.4a 2.5a
HR (95% CI) p 1.40 (1.01–1.96) 0.046 1.36 (1.12–1.65) 0.002 1.03 (0.71–1.49)a 0.896a
Response rate (%)b 2.8 8.1 23.4 31.4 3.1a 1.8a
Nonsquamous (n)c 205 194 618 634 325 156
Median OS (mo) 9.3 8.0 11.0 10.1 15.5 10.3
HR (95% CI) p 0.78 (0.61–1.00) 0.048 0.84 (0.74–0.96) 0.011 0.70 (0.56–0.88) 0.002
Median PFS (mo) 3.1 3.0 5.3 5.0 4.4a 1.8a
HR (95% CI) p 0.82 (0.66–1.02) 0.076 0.95 (0.84–1.06) 0.349 0.47a (0.37–0.60)a0.0001a
Response rate (%)b 11.5 9.0 28.6 22.2 3.4a 0.0a
a Independently reviewed data.
b Tumor response data not available for some patients in each category.
c Nonsquamous histology comprises adenocarcinoma, large cell, and other histologies.
CI, confidence interval; HR, hazard ratio; N, number of randomized patients; OS, overall survival; PFS, progression-free survival.
TABLE 4. Percentage of Patients with Selected Grade 3/4 Drug-Related Toxicities for Three Pemetrexed Studies
Toxicity
Second-Line
Pemetrexed
vs. Docetaxel
First-Line Cisplatin  Pemetrexed
vs. Cisplatin  Gemcitabine
Maintenance
Pemetrexed
vs. Placebo
Pemetrexed
(n  265)
Docetaxel
(n  276)
Cisplatin  Pemetrexed
(n  839)
Cisplatin  Gemcitabine
(n  830)
Pemetrexed
(n  441)
Placebo
(n  222)
Anemia 4.2 4.3 5.6 9.9 2.7 0.5
Neutropenia 5.3 40.2 15.1 26.7 2.9 0.0
Thrombocytopenia 1.9 0.4 4.1 12.7 2.0 0.5
Febrile neutropenia 1.9 12.7 1.3 3.7 0.7 0.0
Fatigue 5.3 5.4 6.7 4.9 5.0 0.5
Vomiting 1.5 1.1 6.1 6.1 0.2 0.0
n, number of patients.
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first-line study, the assessment of quality of life was the
primary end point, and 446 patients were randomly assigned
to receive carboplatin plus pemetrexed or carboplatin plus
gemcitabine. When compared with the other existing first-
line study,7 however, the Norwegian study has several dis-
parities including differences in sample size, treatment regi-
mens (including the combination agent of carboplatin versus
cisplatin), dosing, baseline patient and disease characteristics,
standard of care in Norway, and statistical analyses.28 In
addition, in the Norwegian study, the number of treatment
cycles was limited to four, and the pemetrexed dose was
automatically reduced by 25% for patients older than 75
years. The baseline patient and disease characteristics of the
Norwegian study differed from those of the three studies we
examined. Two of the three studies excluded patients with a
PS of 2,7,19 whereas 11 to 12% of patients had PS 2 in the
second-line study.17 The Norwegian trial, however, reported
22 to 23% of patients with a PS of 2. Additionally, because
the Norwegian trial was not designed for subgroup analyses,
the histology findings should be interpreted with caution, as
acknowledged by the publication’s authors.7,19,28
The consistency of the pemetrexed treatment effect
across these three studies suggests a possible underlying
molecular basis for the effect, related to the mechanism of
action of pemetrexed. Pemetrexed is an antifolate with mul-
tiple enzyme targets affecting purine and pyrimidine synthe-
sis. The primary target of pemetrexed is thymidylate synthase
(TS), and secondary targets are dihydrofolate reductase and
glycinamide ribonucleotide formyl transferase.29,30 In pre-
clinical studies, reduced sensitivity to pemetrexed has been
correlated with an overexpression of TS.31–33 A study of
specimens from chemonaive patients with early-stage adeno-
carcinoma or squamous cell carcinoma evaluated TS using
immunohistochemistry and real-time polymerase chain reac-
tion. Patients with squamous cell carcinoma had significantly
higher (p  0.0001) baseline expression of both the TS gene
and protein than patients with adenocarcinoma.34 Research on
freshly explanted human tumor specimens showed that
mRNA gene expression related to pemetrexed mechanism of
action correlated with in vitro chemosensitivity to pem-
etrexed,35 and low levels of TS (as well as glycinamide
ribonucleotide formyl transferase, dihydrofolate reductase,
and MRP4) gene expression significantly correlated with
chemosensitivity to pemetrexed.35 Prospective studies are
needed to validate TS or other enzymes as a robust candidate
biomarker for pemetrexed activity in NSCLC.
These results across three lines of therapy and in three
separate studies demonstrate the consistency of the pem-
etrexed treatment effect for nonsquamous patients with
NSCLC; however, the comparison of different patient popu-
lations in different lines of therapy might also be considered
a limitation of these analyses. Future studies evaluating
pemetrexed activity should include histology as a randomiza-
tion factor and in prespecified analyses.
Comprehensive analyses of these three large, random-
ized, phase III NSCLC studies of three different lines of
therapy (first line, maintenance, and second line) consistently
demonstrate significant interactions between NSCLC histol-
ogy and a pemetrexed treatment effect, regardless of the
control arm. The analyses indicate the superior efficacy of
pemetrexed in nonsquamous patients and a favorable safety
profile compared with other standard treatment options. Thus,
histology is predictive of the improved efficacy of pem-
etrexed in patients with nonsquamous NSCLC.
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